Creating better health for people and a brighter future for the world is Takeda’s purpose. The science and technology we advance are constantly evolving, but through our enduring values our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while creating an exceptional experience for our people.
The work we do transforms lives, helping patients with limited or no treatment options in our core therapeutic and business areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. We’re taking on big challenges that require new ways of thinking based on the unique needs of patients – including innovating across our operations and value chain, increasing tailored access solutions to the medications and vaccines we produce while helping address disparities within the health care ecosystem.
We are building one of the most exciting and diverse pipelines in the industry. We follow science and aim to unlock innovation wherever it originates – whether we are developing a therapy in one of our laboratories or through our more than 200 partnerships. Together with our investments in data and digital technologies, we aim to improve the patient experience and revolutionize our approach to science.
Takeda is headquartered in Tokyo with a global hub in Cambridge, Massachusetts. We have a presence in approximately 80 countries and regions, a network of manufacturing sites around the world, and major research centers in Japan and the United States. Our global scale and strong portfolio of transformative treatments have and will continue to generate momentum and fuel innovation.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.
Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments, almost all of which were homegrown in our laboratories.
Stallergenes Greer is a fully integrated global biopharmaceutical company specialising in the research, diagnosis, and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services. The Group’s extensive product portfolio, available in multiple formulations (subcutaneous, sublingual drops and tablets), offers patients innovative solutions to improve quality of life for people with allergies. A world leader in allergen immunotherapy, Stallergenes Greer has an extensive global footprint and the largest allergen and finished AIT product manufacturing capacity globally.
Our purpose is to enable precision medicine to improve life for people with allergies. Our strategy is designed to achieve our ambition of being the world’s leading allergen immunotherapy company for the long-term and deliver sustainable value to all our stakeholders: patients, the medical community, healthcare systems, colleagues, and our shareholder. To achieve our ambition, our strategy is based on four pillars:
Menarini Asia-Pacific is a member of the Menarini Group, the world's largest Italian biopharmaceutical company with a heritage of over 130 years and over 17,000 employees in more than 140 countries. Here in Asia-Pacific, Menarini's vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval, and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including
Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men's Health. For more information, visit www.menariniapac.com
EUROIMMUN is a leading manufacturer of medical laboratory products for allergy, autoimmune, infection and molecular diagnostics. EUROIMMUN’s in vitro allergy diagnostics portfolio includes a comprehensive spectrum of allergen extracts in more than 65 EUROLINE profiles for efficient multiparameter detection of specific IgE antibodies. Products encompass indication-oriented profiles (e.g. food, inhalation, atopy, insect venoms or pediatrics), as well as region-specific profiles which take into account local allergen exposure. The product range is complemented by selected profiles for molecular allergy diagnostics (peanut, milk, pediatric food allergies, insect venoms, pollens). These allow differentiation of primary sensitisations from cross reactions, as well as high-risk from low-risk reactions. The allergy product range is complemented by flexible automation solutions.
BioLegend creates world-class, cutting-edge antibodies and reagents across a diverse set of applications—from flow cytometry to immunoassays to multiomics.
We’re accelerating research and discovery by providing high-quality, purpose-driven products for outstanding value. With 30,000 trusted reagents, 100,000+ citations in peer-reviewed publications, and a dedicated team to create custom solutions for your lab, there’s nothing our expertise doesn’t cover. Discover the BioLegend difference and see how it can make an impact in your lab. Learn more at bioLegend.com.
Who we are
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030, with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.
What we do
We prioritise innovation in vaccines and specialty medicines to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four core therapeutic areas: infectious disease, HIV, respiratory/immunology, and oncology.
Vaccines: Our unrivalled portfolio targets infectious diseases at every stage of life helping protect people from shingles, meningitis, flu, polio, measles and many more.
Specialty Medicines: We are global leaders in HIV medicines, pioneering new long-acting therapies and HIV prevention. We focus on life-changing cancer medicines and novel treatments for other immune-mediated diseases.
General Medicines: From inhaled medicines for asthma and COPD to antibiotics to medicines for skin diseases, we make life better for millions of people in over 112 countries.
For more information, please visit: www.gsk.com
Hyphens Pharma focuses on the sales and marketing of specialty pharmaceutical products in selected ASEAN countries. Listed on the Catalist board of the Singapore Exchange (SGX), the group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines and is supplemented by a marketing and distribution network covering 10 additional markets. Our vision is to provide better quality of life to patients, we are constantly on the pulse of our industry’s innovation to meet patients’ needs. Together, we can improve the healthcare of this world.
At Moderna, we're transforming the future of medicine. Our mission is to deliver the greatest possible impact to people through mRNA medicines.
Our future lies in mRNA medicines, the software of life that’s inside all of us. A scientific breakthrough that gives a set of instructions to direct cells to make proteins that prevent and fight disease.
We have dreams to build on, trails to blaze, lives to improve. We are the fearless pioneers who believe in “possible.”
Moderna. This changes everything.
Tembusu Healthcare, headquartered in Singapore, is a healthcare company that focuses on understanding patient’s needs and partnering with the best in the world to bring patients appropriate care. We provide commercial services to develop and distribute medical devices and pharmaceutical products relating to allergy.
Establish in 2001, Agnitio Science & Technology Inc, is a manufacturer specializing in the research, development and production of microprotein chip. We contribute for advancing platform in the fields of allergy diagnostics, clinical immunology and life science.
Our company is certified with ISO13485;2016 and GMP. And our products have the certification of CE, Taiwan FDA and China FDA. Products range including Agnitio BioIC® System, various of allergy panels, cytokines, OEM/ODM nitrocellulose slides.
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Dear Friends and Colleagues,
Allergic diseases and asthma are a rapidly growing health problem worldwide with a marked socio-economic impact. Alongside rapid environmental and lifestyle changes, the fast-evolving economies in Asia-Pacific face an increasing burden of allergic diseases. Advances in science, epidemiology, epigenetics, innovation, and technology continually challenge countries in the post pandemic world.
The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) together with the Allergy and Clinical Immunology Society of Singapore (ACIS) will host the APAAACI 2023 International Conference from the 23rd – 26th October 2023 in Singapore. The theme of the Conference is “The Innovation Revolution: Allergy, Asthma and Immunology”.
The scientific program is being developed as a well-woven combination of cutting-edge advances and practical clinical aspects in allergy, asthma and clinical immunology, addressing the needs of both clinicians and researchers across specialties working in this space. With key international, regional, and national opinion leaders, this will be a truly unique platform for leaders, colleagues, and junior members to share knowledge, network and interact for the best scientific exchange and future collaborations. We hope the Conference will provide a unique platform as a knowledge base in the treatment and prevention of Allergies, Asthma, and Immunologic Disease.
On behalf of the APAAACI and ACIS, we welcome our industry partners to be part of this Conference. Your support will play an integral part in making the Conference a scientifically rewarding events for all those who participate. Together we can make a difference to the community at large.
Let’s make the APAAACI 2023 International Conference a success! We look forward to your active participation!
Prof. Jiu Yao Wang
Prof. Ruby Pawankar
Dr. Liew Woei Kang